EA
FRTX

Emerald Acquisition’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Emerald Acquisition’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$13K Hold
14
– – ﹤0.01% 2965
2016
Q2 		$20K Buy
+14
New +$18K ﹤0.01% 2971

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
CAM
ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Acquisition's FRTX Position: Q3 2016 in Review

Emerald Acquisition held its Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) position steady in Q3 2016 at 14 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #2965.

Emerald Acquisition first reported a position in FRTX in Q2 2016 and has held it in 2 quarters since. The position peaked at $20K in Q2 2016. 36 funds tracked by Wall St. Rank hold FRTX as of Q3 2016.

  • Emerald Acquisition held 14 shares of Fresh Tracks Therapeutics, Inc. Common Stock worth $13K as of Q3 2016.
  • Emerald Acquisition left its Fresh Tracks Therapeutics, Inc. Common Stock share count unchanged in Q3 2016.
  • Fresh Tracks Therapeutics, Inc. Common Stock made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2965 holding.
  • Emerald Acquisition first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $20K in Q2 2016.
  • 36 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.